$TLX

Telix Pharmaceuticals Ltd

Telix Pharmaceuticals develops and commercializes diagnostic imaging agents and therapies for cancer and other diseases. Its products include Illuccix, TLX250-Px and TLX101-Px, and it is developing imaging and therapeutic product candidates, including TLX591-Tx, which is being evaluated in a Phase 3 clinical trial for advanced prostate cancer. Telix also develops existing commercial products for additional indications and pursues regulatory authorizations in multiple jurisdictions, directly or with regional commercial partners. Telix makes money through sales of its commercial products. It also enters collaborations, strategic alliances and licensing arrangements, and acquires or licenses products, technologies and intellectual property. Telix is headquartered in North Melbourne, Australia.

No enriched coverage for $TLX in the last 7 days.

No SEC Form 4 filings for $TLX in the last 30 days.

See all $TLX insider activity →
Low

Telix Pharmaceuticals Limited: Telix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has joined the Thera4Care initiative to evaluate its FAP-targeting therapy candidate, TLX400-Tx, with terbium-161. The collaboration aims to accelerate the development of next-generation theranostics for cancer treatment, focusing on ovarian, pancreatic cancers, and sarcomas. Telix will contribute to preclinical and clinical activities, with data expected to inform future development directions.

Telix Pharmaceuticals (TLX) Joins Trial of FAP-Targeting Therapy

Telix Pharmaceuticals (TLX) has joined the Thera4Care consortium to conduct a Phase 1 trial of its FAP-targeting therapy, 161Tb-DOTAGA.Glu.(FAPi)2, for metastatic solid tumors, including ovarian, pancreatic cancers, and sarcomas. This is an early-stage development update, with no clinical results or changes to Telix's plans.

Wedbush reiterates Telix Pharmaceuticals stock rating at $22 target

Wedbush reiterated an Outperform rating and $22 price target for Telix Pharmaceuticals (TLX) after its Capital Markets Day. The company reaffirmed 2026 revenue guidance of $950M-$970M and expects $1.5B in 2027 revenue, including $300M from ITM. TLX reported 1H 2026 revenue of AUD 477M, up 22% YoY, with net profit of AUD 38M. The company has three FDA-approved imaging products and aims for six by this time next year.

TLX sentiment & insider activity

Recent TLX coverage spans financial news, earnings and mergers & acquisitions.

What's driving TLX

AlphAI scores every news story that mentions TLX with an AI model for sentiment and relevance, and aggregates insider trades from Telix Pharmaceuticals Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TLX

Score

Telix Pharmaceuticals Limited: Telix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has joined the Thera4Care initiative to evaluate its FAP-targeting therapy candidate, TLX400-Tx, with terbium-161. The collaboration aims to accelerate the development of next-generation theranostics for cancer treatment, focusing on ovarian, pancreatic cancers, and sarcomas. Telix will contribute to preclinical and clinical activities, with data expected to inform future development directions.

Telix Pharmaceuticals (TLX) Joins Trial of FAP-Targeting Therapy

Telix Pharmaceuticals (TLX) has joined the Thera4Care consortium to conduct a Phase 1 trial of its FAP-targeting therapy, 161Tb-DOTAGA.Glu.(FAPi)2, for metastatic solid tumors, including ovarian, pancreatic cancers, and sarcomas. This is an early-stage development update, with no clinical results or changes to Telix's plans.

Wedbush reiterates Telix Pharmaceuticals stock rating at $22 target

Wedbush reiterated an Outperform rating and $22 price target for Telix Pharmaceuticals (TLX) after its Capital Markets Day. The company reaffirmed 2026 revenue guidance of $950M-$970M and expects $1.5B in 2027 revenue, including $300M from ITM. TLX reported 1H 2026 revenue of AUD 477M, up 22% YoY, with net profit of AUD 38M. The company has three FDA-approved imaging products and aims for six by this time next year.

Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push

Telix Pharmaceuticals (NASDAQ:TLX) aims for $1.5B in revenue next year, driven by its prostate cancer imaging and therapy programs. Key studies include BiPASS for PSMA-PET imaging and OPTIMAL-PSMA for TLX597-Tx therapy. The company also advances programs for brain and kidney cancer, with FDA approvals expected for PIXCLARA and a decision pending for Zircaix. Telix expects six approved products by next year, subject to regulatory approvals.

$TLXHighAI 9/10

Telix Reports Third Quarter 2026 Financial Performance

Telix Pharmaceuticals reported Q3 2026 revenue of $245M, up 19% YoY, driven by strong demand for its PSMA products. Precision Medicine revenue grew 30% to $201M. The FDA approved Pixclara for glioma imaging, and the company completed BiPASS study enrollment. Telix also announced a merger with ITM, expecting FY 2026 revenue to exceed $1B.

A scarce radioactive material studied for cancer treatment could be made in the U.S.

Telix Pharmaceuticals and Ekalia (a joint venture between IBA and Framatome) are collaborating to establish U.S. production of astatine-211 (211At), a rare radioisotope for cancer treatment. The partnership will use IBA's cyclotron technology and Telix's U.S. radiopharmacy infrastructure. Telix aims to advance its alpha therapy pipeline, including TLX102-Tx for glioblastoma, and support third-party research.

$IONSHighAI 8/10

FDA Drug Approvals In September 2026

The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.

Product launch round-up: 13 October 2026

Telix announced US commercial availability of floretyrosine F 18, distributed by PharmaLogic, for differentiating glioma. Knight Therapeutics launched Tavalisse in Brazil for chronic immune thrombocytopenia, licensed from Rigel Pharmaceuticals.

Related tickers